Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model

Raymond Cha; Michael J. Rybak

doi:10.1128/AAC.47.6.1984-1987.2003

Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model

Raymond Cha
, Michael J. Rybak

Pharmacy

Wayne State University
E. Applebaum Coll. Pharm./Hlth. Sci.

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Potential alternatives, including linezolid, adjunctive rifampin, and moxifloxacin, were evaluated against vancomycin-tolerant (P9802-020) and vancomycin-susceptible clinical isolates of Streptococcus pneumoniae in an in vitro pharmacodynamic model. Vancomycin exhibited maximal killing of 2-log₁₀ CFU/ml against P9802-020. Linezolid, moxifloxacin, and linezolid plus rifampin exhibited 99.9% killing against both isolates. These alternatives should be considered for further evaluation against vancomycin-tolerant S. pneumoniae.

Original language	English
Pages (from-to)	1984-1987
Number of pages	4
Journal	Antimicrobial Agents and Chemotherapy
Volume	47
Issue number	6
DOIs	https://doi.org/10.1128/AAC.47.6.1984-1987.2003
State	Published - Jun 1 2003

Access to Document

10.1128/AAC.47.6.1984-1987.2003

Fingerprint

Dive into the research topics of 'Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model'. Together they form a unique fingerprint.

Cite this

@article{2d0a29b5e1bc4631b47d78384c33df7d,

title = "Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model",

abstract = "Potential alternatives, including linezolid, adjunctive rifampin, and moxifloxacin, were evaluated against vancomycin-tolerant (P9802-020) and vancomycin-susceptible clinical isolates of Streptococcus pneumoniae in an in vitro pharmacodynamic model. Vancomycin exhibited maximal killing of 2-log10 CFU/ml against P9802-020. Linezolid, moxifloxacin, and linezolid plus rifampin exhibited 99.9\% killing against both isolates. These alternatives should be considered for further evaluation against vancomycin-tolerant S. pneumoniae.",

author = "Raymond Cha and Rybak, \{Michael J.\}",

year = "2003",

month = jun,

day = "1",

doi = "10.1128/AAC.47.6.1984-1987.2003",

language = "English",

volume = "47",

pages = "1984--1987",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "6",

}

Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model. / Cha, Raymond; Rybak, Michael J.
In: Antimicrobial Agents and Chemotherapy, Vol. 47, No. 6, 01.06.2003, p. 1984-1987.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model

AU - Cha, Raymond

AU - Rybak, Michael J.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Potential alternatives, including linezolid, adjunctive rifampin, and moxifloxacin, were evaluated against vancomycin-tolerant (P9802-020) and vancomycin-susceptible clinical isolates of Streptococcus pneumoniae in an in vitro pharmacodynamic model. Vancomycin exhibited maximal killing of 2-log10 CFU/ml against P9802-020. Linezolid, moxifloxacin, and linezolid plus rifampin exhibited 99.9% killing against both isolates. These alternatives should be considered for further evaluation against vancomycin-tolerant S. pneumoniae.

AB - Potential alternatives, including linezolid, adjunctive rifampin, and moxifloxacin, were evaluated against vancomycin-tolerant (P9802-020) and vancomycin-susceptible clinical isolates of Streptococcus pneumoniae in an in vitro pharmacodynamic model. Vancomycin exhibited maximal killing of 2-log10 CFU/ml against P9802-020. Linezolid, moxifloxacin, and linezolid plus rifampin exhibited 99.9% killing against both isolates. These alternatives should be considered for further evaluation against vancomycin-tolerant S. pneumoniae.

UR - https://www.scopus.com/pages/publications/0038440779

U2 - 10.1128/AAC.47.6.1984-1987.2003

DO - 10.1128/AAC.47.6.1984-1987.2003

M3 - Article

C2 - 12760880

AN - SCOPUS:0038440779

SN - 0066-4804

VL - 47

SP - 1984

EP - 1987

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 6

ER -

Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model

Abstract

Access to Document

Other files and links

Fingerprint

Cite this